A Real-World Human Experience Study of Zhixuan Analgesic Tablets in the Treatment of Tension-Type Headache

ZHUANG Aolin1,2, CHEN Juan1, QU Wensheng2, LIU Na2

Neural Injury and Functional Reconstruction ›› 2026, Vol. 21 ›› Issue (10) : 580-583.

PDF(951 KB)
中国科技核心期刊
美国《化学文摘》CAS数据库收录
日本科学技术振兴机构数据库收录
湖北省优秀期刊
中国知网网络首发期刊
PDF(951 KB)
Neural Injury and Functional Reconstruction ›› 2026, Vol. 21 ›› Issue (10) : 580-583. DOI: 10.16780/j.cnki.sjssgncj.20261254

A Real-World Human Experience Study of Zhixuan Analgesic Tablets in the Treatment of Tension-Type Headache

  • ZHUANG Aolin1,2, CHEN Juan1, QU Wensheng2, LIU Na2
Author information +
History +

Abstract

Objective: Based on relevant guidelines from the National Medical Products Administration, this study aims to advance the new drug registration process for Zhixuan Analgesic Tablets and systematically summarize its human use experience in treating tension-type headache (TTH), providing evidence-based support for new drug development and clinical promotion. Methods: A prospective real-world study design was employed, enrolling 250 TTH patients. Patients were administered oral Zhixuan Analgesic Tablets (4 tablets per dose, 3 times daily) for a continuous 12-week intervention. The primary efficacy outcome was the number of monthly headache days; secondary outcomes included response rate, acute analgesic usage days, Visual Analog Scale (VAS) scores, and Headache Impact Test-6 (HIT-6) scores. Safety was also assessed. Results: Of 250 enrolled patients, 232 completed intention-to-treat analysis. Compared with baseline, at the third month of intervention, the mean monthly headache days significantly decreased [(3.63±4.41) days vs. (10.76±3.59) days, P<0.05], with a clinical response rate of 71.55%. Secondary outcomes, including acute analgesic usage days, average/peak VAS scores, and HIT-6 scores, all showed significant reductions compared with baseline (P<0.05). The overall incidence of adverse events during the study was 7.6% (19/250), primarily mild gastrointestinal reactions (5.6%) and mild dizziness (2.21%), with no severe adverse events reported. Conclusion: Real-world evidence indicates that Zhixuan Analgesic Tablets significantly reduce headache frequency, alleviate pain intensity, decrease acute analgesic use, and improve quality of life in TTH patients. The favorable safety profile supports its potential for new drug conversion and clinical implementation.

Key words

Zhixuan Analgesic Tablets; tension-type headache; real-world study; human-use experience

Cite this article

Download Citations
ZHUANG Aolin1,2, CHEN Juan1, QU Wensheng2, LIU Na2. A Real-World Human Experience Study of Zhixuan Analgesic Tablets in the Treatment of Tension-Type Headache[J]. Neural Injury and Functional Reconstruction. 2026, 21(10): 580-583 https://doi.org/10.16780/j.cnki.sjssgncj.20261254
PDF(951 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉